从“虚-瘀-毒”论治慢性阻塞性肺疾病合并睡眠呼吸暂停综合征
张文江1 侯春艳2 樊长征1
1.中国中医科学院西苑医院肺病科,北京 100091;
2.中国中医科学院西苑医院心血管病中心,北京 100091
Treatment of chronic obstructive pulmonary disease combined with sleep apnea syndrome based on "deficiency-stasis-toxin"
ZHANG Wenjiang1 HOU Chunyan2 FAN Changzheng1
1.Department of Respiratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China;
2.Center of Cardiovascular Disease, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
摘要 根据现代医学对慢性阻塞性肺疾病合并睡眠呼吸暂停综合征病理生理的认识,结合传统中医对“毒”邪病因的认识,本病当存在“虚”“瘀”“毒”致病的病因病机。本文着重从“虚”“瘀”“毒”在本病发生发展过程中的相互作用,探索相应的有效治法及方药,对丰富本病的中医病因学、提高临床疗效具有重要意义。
关键词 :
慢性阻塞性肺疾病 ,
睡眠呼吸暂停综合征 ,
固本 ,
祛瘀 ,
解毒
Abstract :According to the development of pathophysiology of chronic obstructive pulmonary disease combined with sleep apnea syndrome in modern medical science, and understanding of the etiology of "toxin" evil in the basic theory of traditional Chinese medicine (TCM), the deficiency, toxin and blood stasis of TCM pathogenesis are involved in the disease. This article focuses on the interaction of "deficiency", "blood stasis" and "toxin" in the process of occurrence and development of the disease, and exploration of the corresponding effective treatment and prescriptions. It is significant to recognize and stress the interaction of them in pathogenicity so as to enrich TCM etiology and improve TCM clinical efficacy in the treatment of chronic obstructive pulmonary disease combined with sleep apnea hypopnea syndrome.
Key words :
Chronic obstructive pulmonary disease
Sleep apnea syndrome
Consolidating body resistance
Removing blood stasis
Expelling superficial evils
基金资助: 北京市科学技术委员会“首都临床特色应用研究与成果推广”项目(Z151100004015136)。
作者简介 : 张文江(1973.7-),男,博士,主任医师,长期从事呼吸系统疾病的临床、科研、教学工作。
[1] He ZM,Yang JJ. Overlap syndrome-sleep apnea syndrome in patients with chronic obstructive pulmonary disease [J]. Int J Respir,2009,29(5):287.
[2] O'Donoghue FJ,Catcheside PG,Ellis EE,et al. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease:prevalence and associated factors [J]. Eur Respir J,2003,21(6):977-984.
[3] Valipour A,Lavie P,Lothaller H,et al. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease [J]. Sleep Med,2011,12(4):367-372.
[4] Mayos M,Hernandez-Plozo L,Farre AM,et al. The effect of nocturnal oxygen therapy in patients with sleep apnea syndrome and chronic airflow limitation [J]. Arac Brononeumol,2001,37(2):65-68.
[5] 曹邦卿,薛汉荣,喻强强.慢性阻塞性肺疾病稳定期中医证候与防御素相关性的理论探讨[J].世界中西医结合杂志,2015,10(3):422-423.
[6] Ganz T. Defensins:antimicrobial peptides of innate immunity [J]. Nat Rev Immunol,2003,3(9):710-720.
[7] Pazgier M,Hoover DM,Yang D,et al. Human beta-defensins [J]. Cell Mol Life Sci,2006,63(11):1294-1313.
[8] Liao Z,Dong J,Hu X,et al. Enhanced expression of human β-defensin 2 in peripheral lungs of patients with chronic obstructive pulmonary disease [J]. Peptides,2012, 38(2):350-356.
[9] 高蔚,翁婷,孟文书.慢性阻塞性肺疾病患者诱导痰中β-防御素2水平及其与NF-κB的相关性[J].实用医学杂志,2011,27(24):4401-4403.
[10] Garvey JF,Taylor CT,McNicholas WT. Cardiovascular disease in obstructive sleep apnea syndrome:the role of intermittent hypoxia and inflammation [J]. Eur Respir J,2009,33(5):1195-1205.
[11] 宋海峰,李南方.炎症因子与阻塞性睡眠呼吸暂停综合征的睡眠结构紊乱[J].医学综述,2009,15(9):1301-1303.
[12] Martin RJ,Bartelson BL,Smith P,et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD [J]. Chest,1999,115(5):1338-1345.
[13] 覃家盟.COPD合并阻塞性睡眠呼吸低通气综合征的临床分析[J].中外妇儿健康,2011,19(6):21-22.
[14] Young T,Palta M,Dempsey J,et al. The occurrence of sleep-disordered breathing among middle-aged adults [J]. N Engl J Med,1993,328(17):1230-1235.
[15] Jelic S. Diagnostic and therapeutic approach to coexistent chronic obstructive pulmonary disease and obstructive sleep apnea [J]. Int J Chron Obstruct Pulmon Dis,2008,3(2):269-275.
[16] 沈宁,邱梦茹,朱雪,等.睡眠呼吸暂停低通气综合征中医辨治思路[J].中医杂志,2015,56(4):297-299.
[17] 张文江,史大卓.瘀毒阻络——慢性阻塞性肺疾病的病因病机初探[J].世界中医药,2012,7(1):7-8.
[18] 苗青,张旭丽,林佳阳,等.80例睡眠呼吸暂停综合征患者中医证型分析[J].中医杂志,2008,49(11):989-991.
[19] 邝浩丹,骆仙芳.王会仍辨治慢性阻塞性肺疾病合并阻塞性睡眠呼吸暂停综合征经验探析[J].浙江中医药大学学报,2013,37(12):1397-1399.
[20] 陈佑林,李珊,赵阳红.名老中医罗泽伦经验方“七味消毒饮”治验数则[J].贵阳中医学院学报,2007,29(2):13-14.
[21] 李娜,姚月华,郑向艺,等.基于中医传承辅助系统治疗阻塞性睡眠呼吸暂停综合征方剂组方规律分析[J].世界睡眠医学杂志,2015,2(1):49-53.
[1]
朱美琳 郑文慧 程莉莉 董有静. 心率变异性在妊娠期疾病中的应用研究进展 [J]. 中国医药导报, 2018, 15(6): 31-34.
[2]
王善全1 刘成洲1 刘同祥2. 阻塞性睡眠呼吸暂停综合征患者血清同型半胱氨酸、胱抑素C表达水平及临床价值 [J]. 中国医药导报, 2018, 15(4): 73-76.
[3]
石清兰 毛德文 陈月桥 吕建林. 解毒化瘀Ⅱ方对HBV相关急性肝衰竭患者外周血Th17、Th1表达及临床疗效的影响 [J]. 中国医药导报, 2018, 15(21): 122-125.
[4]
章陈晨1 宋双双1 刘凌琳1 余鹃春2 熊玮1. 老年慢性阻塞性肺疾病急性加重期合并急性心肌梗死患者的右心功能变化与预后评价 [J]. 中国医药导报, 2018, 15(20): 96-99.
[5]
刘北林 张俣 王利平 王筠 赵静 王海旭. SERPINE2基因rs3795987位点基因多态性与新疆汉族、维吾尔族慢性阻塞性肺疾病的相关性研究 [J]. 中国医药导报, 2018, 15(2): 23-26.
[6]
蔡小琼 张晓莉. 以Cameron适时理论为基础的全程干预模式在慢性阻塞性肺疾病中的应用效果 [J]. 中国医药导报, 2018, 15(2): 151-155.
[7]
王慧 徐晓▲ 闫晓培 阮婷 徐莉. 慢性阻塞性肺疾病患者血清前白蛋白、胆碱酯酶与肺功能的关系 [J]. 中国医药导报, 2018, 15(19): 91-95.
[8]
雷佩珊 苏晓茵 王强 邬志坚. 小青龙汤对慢性阻塞性肺疾病患者气道炎症及临床转归的影响 [J]. 中国医药导报, 2018, 15(18): 131-135,139.
[9]
何颖华1 徐佳2 贾菲1 智建文1 冯丽鹏1 杨祎1 李峨1. 李国栋教授从“瘀”论治结肠黑变病经验总结 [J]. 中国医药导报, 2018, 15(18): 140-142.
[10]
王嘉玲1 刘雯雯1 郑燕婵1 许银姬2▲. 二十四节气理论在慢性阻塞性肺疾病慢病管理中的应用 [J]. 中国医药导报, 2018, 15(15): 143-146.
[11]
许炜茹 张青. 从肺脾辨治罕见汉族经典型卡波西肉瘤验案一则 [J]. 中国医药导报, 2018, 15(12): 148-150.
[12]
田园1 李国勤2 徐慧莲1 李春雨1 屈建峰1 刘玉山1 楚晨1 李慧1. 中医肺康复模式在慢性阻塞性肺疾病稳定期的应用效果 [J]. 中国医药导报, 2018, 15(10): 58-62.
[13]
王善全1 刘成洲1 刘同祥2 . 血清生长分化因子-15、C反应蛋白在慢性阻塞性肺疾病中的表达水平 [J]. 中国医药导报, 2018, 15(1): 68-71.
[14]
杨凯1 郭璐2▲ 刘跃建2 胡蓉1 段文娟3. 辛伐他汀在慢性阻塞性肺疾病大鼠模型中的早期干预作用 [J]. 中国医药导报, 2017, 14(34): 8-12.
[15]
梁凯轶1 余艳芳2 周慧1. 慢性阻塞性肺疾病合并支气管扩张患者的MSCT与肺功能的相关性研究 [J]. 中国医药导报, 2017, 14(34): 102-105.